VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on May 21, 2026. The filing addresses a material definitive agreement regarding the company's debt obligations with Lind Global Asset Management XII LLC ("Lind").
Key Financial Metrics and Debt
- Outstanding Debt: The company holds two senior secured convertible promissory notes with Lind:
- 2025 Note: Original principal of $7,500,000 (issued May 15, 2025).
- 2026 Note: Original principal of $2,400,000 (issued January 7, 2026).
- Penalty Assessment: Due to a covenant breach, an additional amount equal to 10% of the outstanding principal of each note became payable.
- Liquidity and Cash Flow: The filing text does not provide specific values for revenue, profit, operating cash flow, or current liquidity positions.
Material Changes and Covenant Breach
The company failed to comply with a "Market Capitalization Covenant" requiring the maintenance of a minimum market capitalization. This failure triggered the 10% penalty assessment described above. On May 21, 2026, the company and Lind entered into a Waiver and Consent to address this breach.
Outlook, Risks, and Management Commentary
- Waiver Terms: Lind waived its rights to declare amounts due and payable, demand immediate payment, accelerate obligations, or foreclose on collateral resulting from the Market Capitalization Covenant breach, both now and in the future.
- Conversion Rights: Lind retains the right to demand conversion of all or a portion of the notes into common stock. The conversion price is the lower of the current conversion price or 90% of the average of the three lowest VWAPs during the 20 trading days prior to the conversion notice.
- Ownership Cap: Conversions are restricted so that Lind's beneficial ownership does not exceed 4.99% of the outstanding common stock.
- Documentation: The full text of the Waiver will be filed as an exhibit to the Form 10-Q due on or before August 14, 2026.
Investor Verification Checklist
- Verify the current market capitalization of VolitionRx to assess the severity of the covenant breach.
- Confirm the total outstanding principal amount including the 10% penalty assessed on both notes.
- Monitor the upcoming Form 10-Q (due August 14, 2026) for the full text of the Waiver and any additional financial disclosures.
- Assess the risk of dilution if Lind exercises its conversion rights at the discounted price.